Date: 2015-08-27
Type of information: Presentation of results at a congress
phase:
Announcement: presentation of results at the European Society of Cardiology (ESC) Congress in London, UK
Company: Actelion (Switzerland)
Product: Opsumit® (macitentan)
Action
mechanism: endothelin receptor antagonist. Macitentan is an oral dual endothelin receptor antagonist. This means that it is expected to block the receptors (type A and B) which endothelin-1 normally attaches to and activates. Endothelin is a naturally occurring substance that is released from lining of the blood vessels. It is present at raised levels in patients with pulmonary arterial hypertension, causing the blood vessels to constrict and the blood vessel walls to thicken. By blocking endothelin receptors , macitentan is expected to stop endothelin from constricting the blood vessels, thereby leading to a decrease in the blood pressure and a reduction of the symptoms of pulmonary arterial hypertension.
Disease: pulmonary arterial hypertension (PAH)
Therapeutic area: Rare diseases - Cardiovascular diseases - Autoimmune diseases
Country:
Trial details:
Latest
news: * On August 27, 2015, Actelion announced that further information on macitentan (Opsumit®) will be presented during a \'best poster session\' at the European Society of Cardiology (ESC) Congress in London, UK. The poster presentation titled ‘Lack of pharmacokinetic interaction between the dual endothelin receptor antagonist macitentan and the combined oral contraceptive, norethisterone and ethinyl estradiol’. (Abstract P2645)
